OncLive TV

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Reva K. Basho, MD, discusses the emergence of bispecific antibodies in HER2-positive breast cancer.

Mikkael A. Sekeres, MD, discusses the goal of transfusion independence in higher-risk myelodysplastic syndromes.

Catriona Jamieson, MD, PhD, discusses the importance of treating patients with myelofibrosis at diagnosis.

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

Dana Chase, MD, FACOG, gynecologic oncologist, discusses the importance of utilizing genetic testing for BRCA mutations in ovarian cancer.

Martine Extermann, MD, PhD, discusses the utility of single-agent trastuzumab in HER2-positive breast cancer.

Susan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.

Meghan Thompson, MD, discusses the evolving role of minimal residual disease testing in chronic lymphocytic leukemia.

Brad S. Kahl, MD, discusses the emergence of antibody-drug conjugates in lymphoma.

Julie M. Vose, MD, MBA, discusses future research efforts with CAR T-cell therapy in lymphoma.

Alison J. Moskowitz, MD, discusses the challenges of intensifying treatment in Hodgkin lymphoma.

Stephen M. Ansell, MD, PhD, discusses incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.

Lindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.

Daniel C. Danila, MD, discusses factors to consider when selecting a treatment option for patients with nonmetastatic castration-resistant prostate cancer.

William P. Harris, MD, discusses the adoption of immunotherapy in advanced hepatocellular carcinoma.

Hans Lee, MD, discusses the evolving treatment paradigm in relapsed/refractory multiple myeloma.

Jeremy C. Jones, MD, discusses key lessons learned from the phase 3 KEYNOTE-177 trial.

Lyndsay Willmott, MD, discusses the importance of genetic testing in ovarian cancer.

Chris Labaki, MD, discusses racial disparities with regard to mammography screenings during the COVID-19 pandemic.

Quoc-Dien Trinh, MD, discusses findings from a study examining the temporal changes in cancer tests and diagnoses in a large healthcare system in the United States during the COVID-19 pandemic. 

Daniel C. Danila, MD, discusses the integration of advanced imaging in prostate cancer.

Suzanne Lentzsch, MD, discusses the utility of cellular therapies in multiple myeloma.

Joseph Mikhael, MD, discusses treatment selection for early relapse in multiple myeloma.

Su H. Wang, MD, MPH, discusses the rationale for the integration of viral hepatitis screening and care in a hospital system as the first steps for preventing liver cancers like hepatocellular carcinoma.

Kelly Garvin, MA, BSN, RN, discusses the impact of CAR T-cell therapy on the treatment of patients with non-Hodgkin lymphoma.

Chasity Washington, MPH, CHES, discusses strategies for addressing disparities in cancer care.

Nagla Abdel Karim, MD, discusses the rationale for the phase 3 CheckMate-73L trial that is being conducted in patients with stage III non–small cell lung cancer that is unable or not planned to be removed by surgery.

Michael J. Mauro, MD, discusses considerations for early treatment initiation in myelofibrosis.

Meghan Thompson, MD, discusses future research directions in chronic lymphocytic leukemia.